These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 9673403

  • 1. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
    Levy Y, Knutson JC, Bishop C, Shany S.
    Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
    [Abstract] [Full Text] [Related]

  • 2. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 3. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Mar; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
    Campbell MJ, Reddy GS, Koeffler HP.
    J Cell Biochem; 1997 Sep 01; 66(3):413-25. PubMed ID: 9257197
    [Abstract] [Full Text] [Related]

  • 6. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
    Swami S, Krishnan AV, Feldman D.
    Clin Cancer Res; 2000 Aug 01; 6(8):3371-9. PubMed ID: 10955825
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites.
    Frampton RJ, Omond SA, Eisman JA.
    Cancer Res; 1983 Sep 01; 43(9):4443-7. PubMed ID: 6307514
    [Abstract] [Full Text] [Related]

  • 8. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
    Koga M, Eisman JA, Sutherland RL.
    Cancer Res; 1988 May 15; 48(10):2734-9. PubMed ID: 2834048
    [Abstract] [Full Text] [Related]

  • 9. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
    Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP.
    Cancer Res; 1999 Aug 15; 59(16):4023-9. PubMed ID: 10463602
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of 1,25-dihydroxyvitamin D3 on cell-cycle kinetics of T 47D human breast cancer cells.
    Eisman JA, Sutherland RL, McMenemy ML, Fragonas JC, Musgrove EA, Pang GY.
    J Cell Physiol; 1989 Mar 15; 138(3):611-6. PubMed ID: 2925799
    [Abstract] [Full Text] [Related]

  • 13. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP, Urben CM, Strugnell SA, Knutson JC.
    Anticancer Res; 2004 Mar 15; 24(5A):2905-12. PubMed ID: 15517895
    [Abstract] [Full Text] [Related]

  • 14. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
    Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G.
    Prostate; 2003 May 15; 55(3):159-67. PubMed ID: 12692781
    [Abstract] [Full Text] [Related]

  • 15. Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor.
    Dokoh S, Donaldson CA, Haussler MR.
    Cancer Res; 1984 May 15; 44(5):2103-9. PubMed ID: 6324995
    [Abstract] [Full Text] [Related]

  • 16. Biological activities of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 on human promyelocytic leukemic HL-60 cells: effects of fetal bovine serum and of incubation time.
    Okuno S, Inaba M, Nishizawa Y, Morii H.
    Miner Electrolyte Metab; 1995 May 15; 21(1-3):211-6. PubMed ID: 7565452
    [Abstract] [Full Text] [Related]

  • 17. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
    Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP.
    Oncogene; 2000 Oct 19; 19(44):5091-7. PubMed ID: 11042697
    [Abstract] [Full Text] [Related]

  • 18. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, Mais DE, Bissonnette RP, Heyman RA, Nadzan AM, Reichman M, Allegretto EA.
    Chem Biol; 1999 May 19; 6(5):265-75. PubMed ID: 10322128
    [Abstract] [Full Text] [Related]

  • 19. Inhibition by 1alpha,25-dihydroxyvitamin D3 of activin A-induced differentiation of murine erythroleukemic F5-5 cells.
    Nagasaki T, Hino M, Inaba M, Nishizawa Y, Morii H, Otani S.
    Arch Biochem Biophys; 1997 Jul 15; 343(2):181-7. PubMed ID: 9224728
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.